Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease
| Autor: | José Ramón Fernández, Jose Luis Calleja, J. Llaneras, V. Hontangas, J. Fuentes, J.J. Sanchez-Ruano, José María Moreno, Xavier Forns, Rosa Maria Morillas, Lucia Bonet, Juan de la Vega, Carmen Baliellas, Moisés Diago, Susana Llerena, Esther Molina, Maria Cuaresma, M.A. Simón, Mercè Roget, Sergio Rodríguez-Tajes, Alicia Hernandez-Albujar, B. Sacristan, Xavier Torras, Conrado M. Fernández-Rodríguez, Pilar Sánchez Pobre, José A. Carrión, Oreste Lo lacono, Mercedes Vergara, Federico Sáez-Royuela, Mari Carmen Navascués, Sabela Lens, Carmen Lopez, Inmaculada Fernández, Jose Ramon Salcines, Raúl J. Andrade, Montserrat Forné, Miguel Fernández Bermejo, Silvia Montoliu, Gloria Sánchez Antolín |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Cirrhosis DACLATASVIR PLUS ASUNAPREVIR COMPENSATED CIRRHOSIS Health Services for the Aged Population Hepacivirus VIRUS-INFECTION Antiviral Agents Severity of Illness Index 03 medical and health sciences chemistry.chemical_compound Liver disease 0302 clinical medicine Surveys and Questionnaires Internal medicine medicine Humans GENOTYPE 1B 030212 general & internal medicine education Adverse effect Aged Retrospective Studies Aged 80 and over AGED 65 YEARS education.field_of_study Hepatology business.industry Ribavirin HCV INFECTION Gastroenterology Hepatitis C Hepatitis C Chronic Viral Load EFFICACY medicine.disease chemistry Tolerability Spain SAFETY Concomitant Female 030211 gastroenterology & hepatology Interferons RIBAVIRIN business CHRONIC HEPATITIS-C |
| Zdroj: | AMERICAN JOURNAL OF GASTROENTEROLOGY r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname |
| ISSN: | 0002-9270 |
| DOI: | 10.1038/ajg.2017.157 |
| Popis: | OBJECTIVES: Interferon-free therapies have an improved safety and efficacy profile. However, data in elderly patients, who have frequently advanced liver disease, associated comorbidities, and use concomitant medications are scarce. The im of this study was to assess the effectiveness and tolerability of all-oral regimens in elderly patients in real-life clinical practice. METHODS: Retrospective analysis of hepatitis C virus (HCV) patients aged >= 65 years receiving interferon-free regimens within the Spanish National Registry (Hepa-C). RESULTS: Data of 1,252 patients were recorded. Of these, 955 (76%) were aged 65-74 years, 211 (17%) were aged 75-79 years, and 86 (7%) were aged >= 80 years at the start of antiviral therapy. HCV genotype-1b was predominant (88%) and 48% were previous non-responders. A significant proportion of patients had cirrhosis (922; 74%), of whom 11% presented decompensated liver disease. The most used regimens were SOF/LDV (33%), 3D (28%), and SOF/SMV (26%). Ribavirin was added in 49% of patients. Overall, the sustained virological response (SVR12) rate was 94% without differences among the three age categories. Albumin = 75 years (2.59 (1.16-5.83); P = 0.02) and albumin = 75 years) or those with advanced liver disease (albumin |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|